Literature DB >> 18544029

A new method for incorporating functional heparin onto the surface of islets of Langerhans.

Sanja Cabric1, Torsten Eich, Javier Sanchez, Bo Nilsson, Olle Korsgren, Rolf Larsson.   

Abstract

A novel technique is described to conjugate macromolecular heparin complexes to cell surfaces. The method is based on the dual properties of avidin-expressing binding sites for both biotin and a macromolecular complex of heparin. A quartz crystal microbalance with dissipation monitoring (QCM-D) revealed sequential binding of biotin, avidin, and heparin complexes. Large particle flow cytometry confirmed functional integrity. Confocal microscopy of the heparinized islets showed evenly distributed fluorescence. An in vitro Chandler loop model demonstrated that the biocompatibility of the new method is comparable to the previous method used on artificial materials with regard to coagulation and antithrombin uptake. The technique presented allows human islets of Langerhans to successfully be covered with functional heparin as a means to reduce instant blood-mediated inflammatory reactions induced by the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544029      PMCID: PMC2963632          DOI: 10.1089/ten.tec.2007.0312

Source DB:  PubMed          Journal:  Tissue Eng Part C Methods        ISSN: 1937-3384            Impact factor:   3.056


  30 in total

1.  Diabetes. Islet cell transplantation.

Authors:  A M Shapiro; E A Ryan; J R Lakey
Journal:  Lancet       Date:  2001-12       Impact factor: 79.321

2.  Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation.

Authors:  Sanja Cabric; Javier Sanchez; Torbjörn Lundgren; Aksel Foss; Marie Felldin; Ragnar Källen; Kaija Salmela; Annika Tibell; Gunnar Tufveson; Rolf Larsson; Olle Korsgren; Bo Nilsson
Journal:  Diabetes       Date:  2007-05-31       Impact factor: 9.461

3.  Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface.

Authors:  M Johnell; G Elgue; S Thelin; R Larsson; A Siegbahn
Journal:  Scand Cardiovasc J       Date:  2002-12       Impact factor: 1.589

4.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

Authors:  A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

5.  A new murine model of islet xenograft rejection: graft destruction is dependent on a major histocompatibility-specific interaction between T-cells and macrophages.

Authors:  Peter Schmidt; Henrik Krook; Akira Maeda; Olle Korsgren; Birgitta Benda
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

6.  Avidin is a heparin-binding protein. Affinity, specificity and structural analysis.

Authors:  Warren C Kett; Ronald I W Osmond; Lily Moe; Spencer E Skett; Beverley F Kinnear; Deirdre R Coombe
Journal:  Biochim Biophys Acta       Date:  2003-03-17

7.  Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.

Authors:  Matilda Johnell; Graciela Elgue; Rolf Larsson; Anders Larsson; Stefan Thelin; Agneta Siegbahn
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

8.  Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro.

Authors:  Jonas Andersson; Javier Sanchez; Kristina Nilsson Ekdahl; Graciela Elgue; Bo Nilsson; Rolf Larsson
Journal:  J Biomed Mater Res A       Date:  2003-11-01       Impact factor: 4.396

9.  Characterization of heparin surfaces using photoelectron spectroscopy and quartz crystal microbalance.

Authors:  E M E Kristensen; H Rensmo; R Larsson; H Siegbahn
Journal:  Biomaterials       Date:  2003-10       Impact factor: 12.479

10.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation.

Authors:  L Moberg; H Johansson; A Lukinius; C Berne; A Foss; R Källen; Ø Østraat; K Salmela; A Tibell; G Tufveson; G Elgue; K Nilsson Ekdahl; O Korsgren; B Nilsson
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

View more
  7 in total

Review 1.  Imaging the islet graft by positron emission tomography.

Authors:  Olof Eriksson; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

Review 2.  Strategies toward single-donor islets of Langerhans transplantation.

Authors:  A M James Shapiro
Journal:  Curr Opin Organ Transplant       Date:  2011-12       Impact factor: 2.640

Review 3.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

Review 4.  Glycocalyx in Endotoxemia and Sepsis.

Authors:  Michael S Goligorsky; Dong Sun
Journal:  Am J Pathol       Date:  2020-02-06       Impact factor: 4.307

Review 5.  Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?

Authors:  Bo Nilsson; Olle Korsgren; John D Lambris; Kristina Nilsson Ekdahl
Journal:  Trends Immunol       Date:  2010-01       Impact factor: 16.687

6.  Improving engraftment of hepatocyte transplantation using alpha-1 antitrypsin as an immune modulator.

Authors:  Charlotte Lee; Anil Dhawan; Valeria Iansante; Celine Filippi; Ragai Mitry; Joanne Tang; Simon Walker; Raquel Fernandez DaCosta; Siddharth Sinha; Robin D Hughes; Maria Koulmanda; Emer Fitzpatrick
Journal:  J Mol Med (Berl)       Date:  2019-02-28       Impact factor: 4.599

Review 7.  Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives.

Authors:  Louise Coppin; Etienne Sokal; Xavier Stéphenne
Journal:  Cells       Date:  2019-09-27       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.